CA
CCCC icon

CoreCap Advisors’s C4 Therapeutics CCCC Stock Holding History

CoreCap Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-227
Closed -$363 – 2840
2025
Q1 		$363 Buy
227
+99
+77% +$295 ﹤0.01% 2772
2024
Q4 		$461 Buy
+128
New +$636 ﹤0.01% 2545

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CoreCap Advisors's CCCC Position: Q2 2025 in Review

CoreCap Advisors sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 227 shares — an estimated $363 sold.

CoreCap Advisors first reported a position in CCCC in Q4 2024 and held it in 2 quarters. The position peaked at $461 in Q4 2024. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • CoreCap Advisors reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 227 C4 Therapeutics shares in Q2 2025, an estimated $363.
  • CoreCap Advisors first reported a position in C4 Therapeutics in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's C4 Therapeutics position peaked at $461 in Q4 2024.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.